Onyx Biotec confirms no encumbrance on shares in FY26

0 min read Updated on 03 Jun 2026, 08:48 AM

Reviewed by

Riya DScanX News Team

AI Summary

Onyx Biotec Ltd. filed a disclosure with the National Stock Exchange of India Limited confirming no encumbrance on shares for FY26. Managing Director Sanjay Jain submitted the declaration on behalf of the promoters under SEBI Takeover Regulations.

*this image is generated using AI for illustrative purposes only.

Onyx Biotec Ltd has confirmed that no encumbrance was created on its shares during the financial year ended March 31, 2026. The disclosure, submitted to the National Stock Exchange of India Limited, ensures compliance with SEBI regulations regarding substantial acquisition of shares and takeovers.

Managing Director Sanjay Jain provided the declaration on behalf of the promoters, promoter group, and persons acting in concert. The filing confirms that no shares were encumbered directly or indirectly throughout FY26.

The submission was made under Regulation 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. These regulations require periodic disclosures by promoters to maintain transparency regarding shareholding patterns and any potential charges on shares.

Detail	Information
Regulation	SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Specific Sections	Regulation 31(4) and 31(5)
Financial Year	FY26
Period Ended	March 31, 2026
Encumbrance Status	None

The letter, addressed to the Listing Department of the exchange, was digitally signed by Sanjay Jain on April 07, 2026. The company requested that the information be placed on record and acknowledged.

Historical Stock Returns for Onyx Biotec

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.00%	-8.84%	+9.04%	+15.29%	-21.60%	-30.93%

How will the absence of share encumbrance impact Onyx Biotec's ability to raise future capital?

What does this clean status suggest about the promoters' current financial health and future strategic plans?

Could this disclosure make Onyx Biotec a more attractive target for potential acquisitions or mergers?

Read Next Article

Onyx Biotec promoter Sanjay Jain sells 9.78% stake

1 min read Updated on 02 Jun 2026, 12:49 AM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

AI Summary

Onyx Biotec promoter Sanjay Jain disposed of 1,774,000 equity shares, representing 9.78% of the company's total shareholding, on May 29, 2026. The transaction, executed on the National Stock Exchange (NSE), reduced his stake from 21.48% to 11.70%. The total value of the sale was ₹5,43,55,360.

*this image is generated using AI for illustrative purposes only.

Onyx Biotec promoter Sanjay Jain reduced his shareholding by 9.78% through the sale of 1,774,000 equity shares on the National Stock Exchange (NSE) on May 29, 2026. The disposal, valued at ₹5,43,55,360, was disclosed to the company under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Following the transaction, Jain's holding in the pharmaceutical company decreased from 21.48% to 11.70%.

The disclosure was submitted in Form C to Onyx Biotec on May 29, 2026, and subsequently forwarded to the National Stock Exchange of India Limited on May 30, 2026. The filing confirmed that the trade was executed on the market, with no activity reported in the derivatives segment by the promoter.

Transaction Details

The sale involved a significant portion of Jain's equity, executed entirely through the open market mechanism. The transaction details, as per the filing, are outlined below:

Parameter	Details
Promoter Name	Sanjay Jain
Category	Promoter
Shares Disposed	1,774,000
Percentage Disposed	9.78%
Pre-transaction Holding	3,894,600 shares (21.48%)
Post-transaction Holding	2,120,600 shares (11.70%)
Transaction Value	₹5,43,55,360
Date of Disposal	27 May 2026
Date of Intimation	29 May 2026
Mode of Acquisition/Disposal	On Market
Exchange	NSE

The company, represented by CEO/CFO/WTB Harsh Mahajan, disseminated the information to the exchange to ensure compliance with regulatory requirements. The filing noted that the transaction value excludes taxes, brokerage, and other associated charges.

Historical Stock Returns for Onyx Biotec